Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachyphrenia19.10.03.010; 17.03.03.0070.000481%Not Available
Decreased eye contact19.01.02.012; 17.02.05.055--Not Available
Executive dysfunction19.21.02.010--Not Available
Drug effect less than expected08.06.01.0360.000606%Not Available
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.001908%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.001908%Not Available
Electric shock sensation17.02.07.024; 08.06.02.023--Not Available
Gait inability17.02.05.069; 08.01.02.0110.000178%Not Available
Heavy menstrual bleeding21.01.03.0050.000695%Not Available
Illness08.01.03.0910.001355%Not Available
Taste disorder17.02.07.029; 07.14.03.004--Not Available
Therapeutic product effect decreased08.06.01.0500.001302%Not Available
Therapeutic product effect incomplete08.06.01.0520.005242%Not Available
Therapeutic product effect variable08.06.01.0550.000606%Not Available
Therapy non-responder08.06.01.063--Not Available
Brain fog16.32.03.050; 19.21.02.017; 17.02.05.077--Not Available
The 11th Page    First    Pre   11    Total 11 Pages